Jason Brett

2.4k total citations · 1 hit paper
17 papers, 1.9k citations indexed

About

Jason Brett is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Jason Brett has authored 17 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Surgery and 3 papers in Molecular Biology. Recurrent topics in Jason Brett's work include Diabetes Treatment and Management (15 papers), Diabetes Management and Research (8 papers) and Pancreatic function and diabetes (3 papers). Jason Brett is often cited by papers focused on Diabetes Treatment and Management (15 papers), Diabetes Management and Research (8 papers) and Pancreatic function and diabetes (3 papers). Jason Brett collaborates with scholars based in United States, Denmark and United Kingdom. Jason Brett's co-authors include John B. Buse, Wolfgang E. Schmidt, Julio Rosenstock, Giorgio Sesti, Lawrence Blonde, Marcin Zychma, Eduard Montanya, A Falahati, Jonathan Bouchard and Christopher S. Conner and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Jason Brett

17 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

2009 1.2k citations John B. Buse, Julio Rosenstock et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Brett United States	13	1.7k	824	637	418	175	17	1.9k
Matthew Wintle United States	12	1.4k 0.8×	637 0.8×	582 0.9×	308 0.7×	163 0.9×	18	1.6k
Mette Zander Denmark	10	1.1k 0.6×	398 0.5×	599 0.9×	161 0.4×	207 1.2×	13	1.3k
Santiago Tofé Spain	12	1.0k 0.6×	482 0.6×	339 0.5×	270 0.6×	155 0.9×	43	1.3k
Frank Vercruysse United States	19	1.7k 1.0×	583 0.7×	931 1.5×	493 1.2×	261 1.5×	24	2.1k
Brandon K. Bergman United States	5	924 0.5×	397 0.5×	297 0.5×	393 0.9×	299 1.7×	12	1.2k
Trine Vang Skjøth Denmark	12	1.1k 0.6×	384 0.5×	344 0.5×	614 1.5×	304 1.7×	23	1.3k
Federico C. Pérez Manghi United Kingdom	3	877 0.5×	383 0.5×	291 0.5×	375 0.9×	283 1.6×	3	1.1k
Lisbeth V. Jacobsen Denmark	19	969 0.6×	394 0.5×	375 0.6×	296 0.7×	109 0.6×	25	1.2k
Liana K. Billings United States	14	963 0.6×	536 0.7×	338 0.5×	421 1.0×	335 1.9×	48	1.6k
Irfan Vardarli Germany	15	773 0.4×	320 0.4×	405 0.6×	96 0.2×	232 1.3×	32	1.1k

Countries citing papers authored by Jason Brett

Since Specialization

Citations

This map shows the geographic impact of Jason Brett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Brett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Brett more than expected).

Fields of papers citing papers by Jason Brett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Brett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Brett. The network helps show where Jason Brett may publish in the future.

Co-authorship network of co-authors of Jason Brett

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Brett. A scholar is included among the top collaborators of Jason Brett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Brett. Jason Brett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Weng, Wayne, Sheldon X. Kong, Rahul Ganguly, et al.. (2020). The prevalence of cardiovascular disease by vascular bed and impact on healthcare costs in a large, real‐world population with type 2 diabetes. Endocrinology Diabetes & Metabolism. 3(2). e00106–e00106. 8 indexed citations

Weng, Wayne, Ye Tian, Sheldon X. Kong, et al.. (2020). Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting. SHILAP Revista de lepidopterología. 6(1). 5–5. 20 indexed citations

Weng, Wayne, Ye Tian, Sheldon X. Kong, et al.. (2019). The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. Endocrinology Diabetes & Metabolism. 2(3). e00076–e00076. 43 indexed citations

O’Neil, Patrick M., Vanita R. Aroda, Arne Astrup, et al.. (2017). Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obesity and Metabolism. 19(11). 1529–1536. 86 indexed citations

DerSarkissian, Maral, Rachel H. Bhak, Joanna Huang, et al.. (2017). Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population. Current Medical Research and Opinion. 33(6). 1105–1110. 18 indexed citations

Kolotkin, Ronette L., Ken Fujioka, Michael Lyng Wolden, Jason Brett, & Jakob B. Bjorner. (2015). Abstract #610: Improvements in Health-Related Quality of life with Liraglutide 3.0 Mg Compared with Placebo for Weight Management. Endocrine Practice. 21. 118–118. 1 indexed citations

Nandy, Debashis, Christopher M. Johnson, Rita Basu, et al.. (2014). The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diabetes and Vascular Disease Research. 11(6). 419–430. 46 indexed citations

Aroda, Vanita R., Jason Brett, Naum Khutoryansky, & Robert E. Ratner. (2012). Identifying Predictors of Response to Liraglutide in Type 2 Diabetes Using Recursive Partitioning Analysis. Canadian Journal of Diabetes. 36(5). S45–S45. 11 indexed citations

Shepherd, Mark D., et al.. (2012). Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial). Current Medical Research and Opinion. 28(7). 1203–1211. 4 indexed citations

10.

Henry, Robert R., John B. Buse, Giorgio Sesti, et al.. (2011). Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. Endocrine Practice. 17(6). 906–913. 45 indexed citations

11.

Bode, Bruce W., Jason Brett, A Falahati, & Richard E. Pratley. (2011). Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies. The American journal of geriatric pharmacotherapy. 9(6). 423–433. 48 indexed citations

12.

Buse, John B., Alan J. Garber, Julio Rosenstock, et al.. (2011). Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. The Journal of Clinical Endocrinology & Metabolism. 96(6). 1695–1702. 118 indexed citations

13.

Davidson, Jaime A., Jason Brett, A Falahati, & David A. Scott. (2011). Mild Renal Impairment and the Efficacy and Safety of Liraglutide. Endocrine Practice. 17(3). 345–355. 24 indexed citations

14.

Johnston, Stephen S., Christopher S. Conner, Mark Aagren, et al.. (2011). Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care. 34(5). 1164–1170. 142 indexed citations

15.

Davidson, Jaime A., Jason Brett, A Falahati, & David A. Scott. (2010). Mild Renal Impairment and the Efficacy and Safety of Liraglutide. Endocrine Practice. 17(3). 345–355. 64 indexed citations

16.

Buse, John B., Julio Rosenstock, Giorgio Sesti, et al.. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet. 374(9683). 39–47. 1203 indexed citations breakdown →

17.

Oyer, David S., et al.. (2009). A1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial). The American Journal of Medicine. 122(11). 1043–1049. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact